The bone anabolic carotenoids p-hydroxycinnamic acid and β-cryptoxanthin antagonize NF-κB activation in MC3T3 preosteoblasts

Molecular Medicine Reports

Volumn 2, Issue 4, 2009, Pages 641-644

  Yamaguchi, Masayoshi ^a   Weitzmann, M Neale ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone formation; NF B promoter; Osteoblast; Osteoporosis; P hydroxycinnamic acid; cryptoxanthin

Indexed keywords

BETA CRYPTOXANTHIN; CAROTENOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PARA COUMARIC ACID;

ANIMAL CELL; ARTICLE; BONE; CELL LINE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; SIGNAL TRANSDUCTION;

EID: 69549122467     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000150     Document Type: Article

References (23)

1. Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186-1194, 2006.
2. Sugimoto E and Yamaguchi M: Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. Int J Mol Med 5: 515-520, 2000.
3. Yamaguchi M and Gao YH: Inhibitory effect of genistein on bone resorption in tissue culture. Biochem Pharmacol 55: 71-76, 1998. (Pubitemid 28101987)
4. Gao YH and Yamaguchi M: Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med 5: 261-267, 2000.
5. Uchiyama S and Yamaguchi M: β-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. J Cell Biochem 95: 1224-1234, 2005. (Pubitemid 41420129)
6. Lai YL and Yamaguchi M: Phytocomponent p-hydroxycinnamic acid stimulates bone formation and inhibits bone resorption in rat femoral tissues in vitro. Mol Cell Biochem 292: 45-52, 2006.
7. Lai YL and Yamaguchi M: Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures. Int J Mol Med 19: 123-128, 2007.
8. Uchiyama S and Yamaguchi M: Oral administration of β-cryptoxanthin prevents bone loss in ovariectomized rats. Int J Mol Med 17: 15-20, 2006.
9. Yamaguchi M, Lai YL, Uchiyama S and Nakagawa T: Oral administration of phytocomponent p-hydroxycinnamic acid prevents bone loss in ovariectomized rats. Mol Cell Biochem 311: 31-36, 2008.
10. Franzoso G, Carlson L, Xing L, et al: Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11: 3482-3496, 1997. (Pubitemid 28023969)
11. Boyce BF, Xing L, Franzoso G and Siebenlist U: Required and nonessential functions of nuclear factor-kappa B in bone cells. Bone 25: 137-139, 1999. (Pubitemid 29322078)
12. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A and Bravo R: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3: 1285-1289, 1997. (Pubitemid 27508833)
13. Hall TJ, Schaeublin M, Jeker H, Fuller K and Chambers TJ: The role of reactive oxygen intermediates in osteoclastic bone resorption. Biochem Biophys Res Commun 207: 280-287, 1995.
14. Strait K, Li Y, Dillehay DL and Weitzmann MN: Suppression of NF-κ activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med 21: 521-525, 2008. (Pubitemid 351802648)
15. Feng R, Anderson G, Xiao G, et al: SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 109: 2130-2138, 2007. (Pubitemid 46348215)
16. Dai S, Hirayama T, Abbas S and Abu-Amer Y: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222, 2004. (Pubitemid 39195425)
17. Li Y, Li A, Strait K, Zhang H, Nanes MS and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation, through NF-kappaB. J Bone Miner Res 22: 646-655, 2007. (Pubitemid 351339092)
18. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H and Rosier RN: Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res 312: 40-50, 2006. (Pubitemid 41668590)
19. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH and Franceschi RT: Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14: 893-903, 1999. (Pubitemid 29262883)
20. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C and Pacifici R: Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136: 3054-3061, 1995.
21. Nanes MS: Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321: 1-15, 2003. (Pubitemid 37421390)
22. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R and Novack DV: RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118: 2088-2097, 2008. (Pubitemid 351872328)
23. Mellor AL and Munn DH: Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 18: 367-391, 2000.